Cryoglobulinemia future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Kiran Singh (talk | contribs) |
No edit summary |
||
Line 2: | Line 2: | ||
{{Cryoglobulinemia}} | {{Cryoglobulinemia}} | ||
{{CMG}}; | {{CMG}}; {{AE}} {{CZ}} | ||
==Overview== | ==Overview== |
Latest revision as of 14:56, 15 June 2016
Cryoglobulinemia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Cryoglobulinemia future or investigational therapies On the Web |
American Roentgen Ray Society Images of Cryoglobulinemia future or investigational therapies |
Cryoglobulinemia future or investigational therapies in the news |
Blogs on Cryoglobulinemia future or investigational therapies |
Risk calculators and risk factors for Cryoglobulinemia future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Overview
Future or Investigational Therapies
- In patients with acute, severe disease, plasmapheresis has been used in conjunction with high dose steroids and cytoxan.
- Uncontrolled studies demonstrated a reduction in creatinine in up to 87% of patients.